Page last updated: 2024-12-05

mephentermine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mephentermine is a sympathomimetic amine that acts as a stimulant and is used primarily as a nasal decongestant. It is a synthetic compound, not found naturally, and its synthesis involves the reaction of phenylacetone with methylamine. Mephentermine acts by stimulating the release of norepinephrine and dopamine, leading to vasoconstriction, which reduces nasal congestion. It also has central nervous system effects, causing alertness and decreased appetite. Mephentermine's importance lies in its effectiveness as a decongestant, although it is now less commonly used due to potential side effects and the availability of newer medications. Research on mephentermine focuses on its pharmacokinetics, efficacy as a decongestant, potential interactions with other drugs, and its abuse potential. '

sphinganine : A 2-aminooctadecane-1,3-diol having (2S,3R)-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Mephentermine: A sympathomimetic agent with specificity for alpha-1 adrenergic receptors. It is used to maintain BLOOD PRESSURE in hypotensive states such as following SPINAL ANESTHESIA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91486
CHEMBL ID448741
CHEBI ID16566
SCHEMBL ID40592
MeSH IDM0013430
PubMed CID3677
CHEMBL ID1201234
CHEBI ID6755
SCHEMBL ID121178
MeSH IDM0013430

Synonyms (187)

Synonym
smr000471878
MLS001066334
CBIOL_002042
(r-(r*,s*))-2-aminooctadecane-1,3-diol
(2s,3r)-2-amino-1,3-octadecanediol
(2s,3r)-2-aminooctadecane-1,3-diol
CHEBI:16566 ,
gtpl2453
dihydro-d-erythrosphingosine
BSPBIO_001288
IDI1_033758
BIO2_000488
tocris-0749
BIO1_000328
BIO1_001306
NCGC00024767-01
BIO2_000008
BIO1_000817
LMSP01020001
BCBCMAP01_000225
1,3-octadecanediol, 2-amino-, (2s,3r)- (9ci)
erythro-sphinganine
d-erythro-2-amino-1,3-octadecanediol
d-erythro-dihydrosphingosine
spc 102860
d-erythro-1,3-dihydroxy-2-aminooctadecane
d-erythro-dhs
c18-sphingosine, dihydro-
octadecasphinganine
d-erythro-c18-dihydrosphingosine
1,3-octadecanediol, 2-amino-, d-erythro- (8ci)
c18-dihydrosphingosine
1,3-octadecanediol, 2-amino-, [r-(r*,s*)]-
1,3-octadecanediol, 2-amino-, (2s,3r)-
d-erythro-sphinganine
dihydro-c18-sphingosine
2-amino-1,3-dihydroxyoctadecane
764-22-7
C00836
sphinganine
d-erythro-dihydrosphingosine, >=98%
NCGC00024767-02
NCGC00024767-03
einecs 212-116-0
1,3-octadecanediol, 2-amino-, d-erythro-
1,3-octadecanediol, 2-amino-, (r-(r*,s*))-
KBIO3_000015
KBIOGR_000008
KBIO3_000016
KBIO2_005144
KBIO2_002576
KBIO2_000008
KBIOSS_000008
NCGC00024767-04
82E0B6E3-6AE1-425F-A39E-5BED56511028
HMS1989A10
cid_3126
bdbm50244355
sphinganine (d18:0)
BML3-D04
HMS1361A10
HMS1791A10
dihydrospingosine
CHEMBL448741 ,
HMS2232G12
yt0zsd64hm ,
unii-yt0zsd64hm
SCHEMBL40592
sphinganine [inci]
(+)-erythro-dihydrosphingosine
HMS3402A10
SR-01000597679-1
sr-01000597679
AS-60774
c18-dihydro-sphingosine
2-amino-d-erythro-1,3-octadecanediol
[r-(r*,s*)]-2-amino-1,3-octadecanediol
sphinganine (d18:0), d-erythro-sphinganine, powder
d-erythro-dihydro-d-sphingosine
Q27088847
DTXSID501016568
CS-0031629
HY-W019838
dihydrosphingosine (sphinganine)
d-erythro-sphinganine, c18 chain
dihydro-d-erythro-sphingosine
AKOS037645439
KBIO1_000229
DIVK1C_000229
n,2-dimethyl-1-phenylpropan-2-amine
SPECTRUM_001611
IDI1_000229
BSPBIO_000652
BSPBIO_002640
BPBIO1_000718
2-methyl-2-methylamino-1-phenylpropane
hsdb 2172
wyamine
mefentermina [inn-spanish]
mephenterminum [inn-latin]
mephenterdrinum
n,alpha,alpha-trimethylbenzeneethanamine
benzeneethanamine, n,alpha,alpha-trimethyl-
mephetedrine
mephentermine [inn:ban]
n,alpha,alpha-trimethylphenethylamine
mefentermin
mephine
omega-phenyl-tert-butyl-methylamine
n-methyl-omega-phenyl-tert-butylamine
2-methylamino-2-methyl-1-phenylpropane
n-methyl-omega-phenyl-t-butylamine
wyfentermina
wy-585
brn 1363850
vialin
phenethylamine, n,alpha,alpha-trimethyl-
mephenterdrine
mefenterdrin
einecs 202-901-6
n-methylphentermine
benzeneethanamine, n,.alpha.,.alpha.-trimethyl-
mephentermine sulfate
phenethylamine, n,.alpha.,.alpha.-trimethyl-
cas-1212-72-2
NCGC00016570-01
PRESTWICK2_000726
SPECTRUM5_001008
PRESTWICK3_000726
AB00053662
C07889
mephentermine
100-92-5
DB01365
KBIOGR_000735
KBIO2_007227
KBIO2_004659
KBIO3_002140
KBIO2_002091
KBIOSS_002091
PRESTWICK1_000726
SPECTRUM3_001220
NINDS_000229
SPBIO_002591
SPBIO_000608
PRESTWICK0_000726
SPECTRUM4_000188
SPECTRUM2_000474
NCGC00016570-02
NCGC00016570-03
mephentermine sodium
D08180
mephentermine (inn)
bdbm81455
nsc_3677
cas_3677
AKOS006281398
mephenterminum
mefentermina
tez91l71v4 ,
unii-tez91l71v4
CHEMBL1201234
chebi:6755 ,
(1,1-dimethyl-2-phenylethyl)methylamine
mephentermine [vandf]
mephentermine [hsdb]
mephentermine [mi]
n,.alpha.,.alpha.-trimethylphenethylamine
mephentermine [inn]
mephentermine [who-dd]
methyl(2-methyl-1-phenylpropan-2-yl)amine
gtpl7222
SCHEMBL121178
n,.alpha.,.alpha.-trimethylbenzeneethanamine
n,2-dimethyl-1-phenyl-2-propanamine #
fentermin (salt/mix)
n-methyl-.omega.-phenyl-t-butylamine
.omega.-phenyl-tert-butyl-methylamine
n,.alpha.,.alpha.-trimethyl-.beta.-phenethylamine
RXQCGGRTAILOIN-UHFFFAOYSA-N
n-methyl-.omega.-phenyl-tert-butylamine
AB00053662_08
DTXSID4023256
SBI-0051802.P002
n,2-dimethyl-1-phenylpropan-2-amine;n,2-dimethyl-1-phenylpropan-2-amine
Q6817800
BRD-K18194590-065-05-6

Research Excerpts

Overview

Mephentermine is a sympathomimetic amine, frequently used as a vasopressor. It is closely related to amphetamine and methamphetamine.

ExcerptReferenceRelevance
"Mephentermine is a vasopressor drug closely related to amphetamine and methamphetamine. "( Mephentermine dependence in a young Indian adult without psychosis.
Somani, A, 2020
)
3.44
"Mephentermine is a sympathomimetic amine, frequently used as a vasopressor. "( Mephentermine Misuse: An Impending Crisis among Sportspersons.
Arya, S; Bhardwaj, A; Gupta, R; Yadav, J,
)
3.02
"Mephentermine is a sympathomimetic agent derived from methamphetamine which, in Brazil, is restricted to veterinary use."( Mephentermine dependence without psychosis: a Brazilian case report.
da Costa Lima, MD; de Oliveira, JR; de Oliveira, MF; de Sousa, HF, 2010
)
2.52

Dosage Studied

ExcerptRelevanceReference
" In the dosage used the vasoconstrictive effect of methamphetamine was altogether only somewhat more expressed."( [Clinical-pharmacological studies on the effect of mephentermin and methamphetamine on the hemodynamics of the lung circulation].
Förster, W; Kneehans, S; Krause, M; Mährlein, W; Sziegoleit, W, 1975
)
0.25
" In addition, urinary and biliary metabolites of p-hydroxy-MP and p-hydroxy-Ph dosed orally to rat were examined."( Intestinal metabolism of mephentermine and its biliary metabolites in male Wistar rats.
Kobayashi, M; Kozuka, H; Miyahara, T; Mori, M; Uemura, H, 1992
)
0.59
" p-Hydroxymephentermine (p-hydroxy-MP) and p-hydroxyphentermine (p-hydroxy-Ph) were isolated as hydrochlorides from urine of male Wistar rats repeatedly dosed with mephentermine (MP)."( Isolation of urinary p-hydroxylated metabolites of mephentermine and phentermine in male Wistar rats.
Inoue, M; Kozuka, H; Miyahara, T; Mori, MA; Sakai, K; Uy-Yu, N, 1990
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 2.7.11.13 (protein kinase C) inhibitorAn EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
2-aminooctadecane-1,3-diolAn aminodiol that is octadecane bearing two hydroxy substituents at positions 1 and 3 as well as an amino substituent at position 2.
amphetaminesAmines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (21)

PathwayProteinsCompounds
Sphingolipid Metabolism2335
Gaucher Disease2335
Globoid Cell Leukodystrophy2335
Metachromatic Leukodystrophy (MLD)2335
Fabry Disease2335
Krabbe Disease2335
Biosynthesis of Unsaturated Fatty Acids1439
Biosynthesis of Unsaturated Fatty Acids (Tetracosanoyl-CoA)1435
Biosynthesis of Unsaturated Fatty Acids (Docosanoyl-CoA)1431
Biosynthesis of Unsaturated Fatty Acids (Icosanoyl-CoA)1427
Biosynthesis of Unsaturated Fatty Acids (Stearoyl-CoA)1322
Sphingolipid metabolism (integrated pathway)1167
Sphingolipid metabolism overview415
Sphingolipid metabolism: integrated pathway163
Sphingolipid metabolism in senescence97
Synthesis of ceramides and 1-deoxyceramides115
sphingolipid metabolism020
Sphingolipid pathway315
Biochemical pathways: part I0466
Metabolism of sphingolipids in ER and Golgi apparatus144
Sphingolipids metabolism pathway063
Sphingolipid metabolism415
Lipid metabolism321

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency19.95260.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.00060.004023.8416100.0000AID485290
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
acid sphingomyelinaseHomo sapiens (human)Potency89.125114.125424.061339.8107AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency100.00000.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency44.66840.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency31.62280.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency15.23780.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1460
glucocerebrosidaseHomo sapiens (human)Potency17.78280.01268.156944.6684AID2101
IDH1Homo sapiens (human)Potency18.35640.005210.865235.4813AID686970
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency7.94330.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency31.62280.316212.443531.6228AID902; AID924
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency70.79460.354828.065989.1251AID504847
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency28.18380.251215.843239.8107AID504327
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency3.16230.316212.765731.6228AID881
Integrin beta-3Homo sapiens (human)Potency31.62280.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency31.62280.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency3.16230.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Chain A, Ferritin light chainEquus caballus (horse)Potency0.56235.623417.292931.6228AID485281
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency10.00000.00207.533739.8107AID891
gemininHomo sapiens (human)Potency5.70070.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency0.00320.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (91)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID357403Resistance index, ratio of IC50 for 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells to IC50 for human wild type Jurkat cells2007The Journal of biological chemistry, May-25, Volume: 282, Issue:21
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID401373Antimicrobial activity against Prorocentrum micans at 5 ppm1998Journal of natural products, Jun-26, Volume: 61, Issue:6
New ceramide from marine sponge Haliclona koremella and related compounds as antifouling substances against macroalgae.
AID681583TP_TRANSPORTER: cell accumulation (digoxin-sensitive) in Caco-2 cells2004Bioscience, biotechnology, and biochemistry, Dec, Volume: 68, Issue:12
Efflux of sphingoid bases by P-glycoprotein in human intestinal Caco-2 cells.
AID1204009Antiproliferative activity against human T47D cells after 48 hrs incubation by SRB assay2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID401371Antimicrobial activity against Branchiomonas submaria at 1 ppm1998Journal of natural products, Jun-26, Volume: 61, Issue:6
New ceramide from marine sponge Haliclona koremella and related compounds as antifouling substances against macroalgae.
AID101365Median toxic concentration of compound tested in vitro against human leukemia 60 cells2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
Antitumour activity of sphingoid base adducts of phenethyl isothiocyanate.
AID357404Resistance index, ratio of IC50 for 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells to IC50 for human wild type Jurkat cells2007The Journal of biological chemistry, May-25, Volume: 282, Issue:21
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID357402Inhibition of wild type human Jurkat cells after 18 hrs by MTT assay2007The Journal of biological chemistry, May-25, Volume: 282, Issue:21
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
AID401376Antimicrobial activity against Oscillatoria amphibia at 5 ppm1998Journal of natural products, Jun-26, Volume: 61, Issue:6
New ceramide from marine sponge Haliclona koremella and related compounds as antifouling substances against macroalgae.
AID1627821Downregulation of CD98 expression level in mouse FL5.12A cells at 2.5 uM measured at 3 hrs by flow cytometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Effects of stereochemistry, saturation, and hydrocarbon chain length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutrient transporter down-regulation, vacuolation, and cell death.
AID1204006Antiproliferative activity against human HBL100 cells after 48 hrs incubation by SRB assay2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID407129Fungicidal activity against Candida albicans CAI4 in presence of 10 mM ascorbic acid2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Fungicidal activity of truncated analogues of dihydrosphingosine.
AID357393Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR2 mutant cells proliferation after 18 hrs by MTT assay2007The Journal of biological chemistry, May-25, Volume: 282, Issue:21
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
AID407128Fungicidal activity against Candida albicans CAI42008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Fungicidal activity of truncated analogues of dihydrosphingosine.
AID357392Inhibition of 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR1 mutant cells proliferation after 18 hrs by MTT assay2007The Journal of biological chemistry, May-25, Volume: 282, Issue:21
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
AID357394Inhibition of human 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells proliferation after 18 hrs by MTT assay2007The Journal of biological chemistry, May-25, Volume: 282, Issue:21
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID401375Antimicrobial activity against Oscillatoria amphibia at 1 ppm1998Journal of natural products, Jun-26, Volume: 61, Issue:6
New ceramide from marine sponge Haliclona koremella and related compounds as antifouling substances against macroalgae.
AID407127Fungicidal activity against Candida glabrata BG22008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Fungicidal activity of truncated analogues of dihydrosphingosine.
AID101364Median growth inhibitory concentration of compound tested in vitro against human leukemia 60 cells2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
Antitumour activity of sphingoid base adducts of phenethyl isothiocyanate.
AID357405Resistance index, ratio of IC50 for 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol-resistant human Jurkat SBR3 mutant cells to IC50 for human wild type Jurkat cells2007The Journal of biological chemistry, May-25, Volume: 282, Issue:21
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
AID1627820Cytotoxicity against mouse FL5.12A cells after 48 hrs by DAPI staining-based flow cytometric analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Effects of stereochemistry, saturation, and hydrocarbon chain length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutrient transporter down-regulation, vacuolation, and cell death.
AID1204008Antiproliferative activity against human SW1573 cells after 48 hrs incubation by SRB assay2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1627822Induction of vacuolation in mouse FL5.12A cells assessed as vacuolation score at 2.5 uM measured at 3 hrs by fluorescence microscopic analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Effects of stereochemistry, saturation, and hydrocarbon chain length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutrient transporter down-regulation, vacuolation, and cell death.
AID401372Antimicrobial activity against Branchiomonas submaria at 5 ppm1998Journal of natural products, Jun-26, Volume: 61, Issue:6
New ceramide from marine sponge Haliclona koremella and related compounds as antifouling substances against macroalgae.
AID407131Induction of endogenous ROS accumulation in Candida albicans CAI4 after 3 hrs by 2',7'-dichlorofluorescein diacetate staining2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Fungicidal activity of truncated analogues of dihydrosphingosine.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1204010Antiproliferative activity against human WiDr cells after 48 hrs incubation by SRB assay2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1204007Antiproliferative activity against human HeLa cells after 48 hrs incubation by SRB assay2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346619Human TRPM3 (Transient Receptor Potential channels)2005Molecular pharmacology, Mar, Volume: 67, Issue:3
Activation of the melastatin-related cation channel TRPM3 by D-erythro-sphingosine [corrected].
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (228)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990179 (78.51)18.7374
1990's7 (3.07)18.2507
2000's16 (7.02)29.6817
2010's20 (8.77)24.3611
2020's6 (2.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.66 (24.57)
Research Supply Index5.51 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index123.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (71.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials7 (2.94%)5.53%
Reviews0 (0.00%)6.00%
Reviews14 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies19 (7.98%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
Other198 (83.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparative Analytical Study of Intravenous Bolus Dose of Mephentermine and Phenylephrine for Hemodynamic Stability During Elective Cesarean Section Under Spinal Anesthesia at KIST Medical College and Teaching Hospital [NCT05706727]Phase 342 participants (Anticipated)Interventional2023-03-23Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]